Suppr超能文献

静脉注射免疫球蛋白治疗前川崎病中类固醇激素受体表达降低

Decreased Steroid Hormone Receptor Expression in Kawasaki Disease Before IVIG Treatment.

作者信息

Huang Ying-Hsien, Chen Kuang-Den, Lo Mao-Hung, Cai Xin-Yuan, Kuo Ho-Chang

机构信息

Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

出版信息

Front Pediatr. 2019 Feb 4;7:7. doi: 10.3389/fped.2019.00007. eCollection 2019.

Abstract

Kawasaki disease (KD) is anacute febrile coronary vasculitis disease in children. In general, this disease can be treated with a single dose of 2 g/kg intravenous immunoglobulin (IVIG). However, the best timing for administering steroid treatment in acute-stage KD is still under debate. In this study, we recruited 174 participants to survey the transcript levels of steroid hormone receptors in KD patients. The chip studies consisted of 18 KD patients that were analyzed before IVIG treatment and at least 3 weeks after IVIG administration, as well as 36 control subjects, using GeneChip® HTA 2.0. Another cohort consisting of 120 subjects was analyzed to validate qRT-PCR. Our microarray study demonstrated significant downregulated expressions of the mRNA levels of NR1A2, RORA, NR4A1-3, THRA, and PPARD in KD patients in comparision to the controls. However, these genes increased considerably in KD patients after IVIG administration. After PCR validation, our data only revealed decreased NR4A2 mRNA expression in the KD patients compared to those of the controls, which increased after they received IVIG treatment. Our study is the first to report the potential effective utilization of steroid treatment in KD. Prior to IVIG treatment, decreased steroid receptors allowed for the reduced treatment role of steroids. However, after IVIG treatment, increased steroid receptors indicate that steroids are effective as a supplementary treatment for KD.

摘要

川崎病(KD)是一种儿童急性发热性冠状动脉血管炎疾病。一般来说,这种疾病可用单剂量2 g/kg静脉注射免疫球蛋白(IVIG)进行治疗。然而,KD急性期类固醇治疗的最佳时机仍存在争议。在本研究中,我们招募了174名参与者来调查KD患者中类固醇激素受体的转录水平。芯片研究包括18名KD患者,在IVIG治疗前和IVIG给药后至少3周进行分析,以及36名对照受试者,使用GeneChip® HTA 2.0。另一个由120名受试者组成的队列进行了分析以验证定量逆转录聚合酶链反应(qRT-PCR)。我们的微阵列研究表明与对照组相比,KD患者中NR1A2、RORA、NR4A1 - 3、THRA和PPARD的mRNA水平表达显著下调。然而,这些基因在KD患者接受IVIG给药后显著增加。经过PCR验证,我们的数据仅显示KD患者中NR4A2 mRNA表达与对照组相比降低,在他们接受IVIG治疗后增加。我们的研究首次报道了类固醇治疗在KD中潜在的有效应用。在IVIG治疗前,类固醇受体减少使得类固醇的治疗作用降低。然而,IVIG治疗后类固醇受体增加表明类固醇作为KD的辅助治疗是有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验